Having trouble viewing this email? View in your browser.

Please join us virtually at ECCMID on Friday, 9 July 2021 for an integrated symposium on vaccination. We are pleased to have Professor Marc J.M. Bonten MD, PhD as our ESCMID-appointed chair for this programme.

Revising the Paradigm: The Importance of Adult Vaccination Against Respiratory Diseases
Friday, 9 July 2021 | 13:15–15:15 CET
Virtual from Austria

Aim of the Session:
The current global pandemic has brought to light the substantial burden of infectious respiratory diseases in adults, particularly older adults and those with chronic medical conditions that may increase their risk. Many infectious respiratory diseases, such as pneumococcal pneumonia and COVID-19 are vaccine-preventable. This symposium aims to provide a forum for two separate discussions:

1. Pneumococcal vaccination for adults: evolving with the changing landscape
2. Development of an mRNA Covid-19 vaccine in a strategic collaboration



Welcome and Opening Remarks
Chair Prof. Ralf René Reinert (Germany)
ESCMID-appointed Chair Prof. Marc J.M. Bonten (the Netherlands)


Pneumococcal Conjugate Vaccination for Adults: Need for Expanded Valent Conjugate Vaccines
Dr. Peter Paradiso (USA)


Assessing the Burden of Pneumococcal Pneumonia in Adults
Prof. Antoni Torres (Spain)


Pneumococcal Panel Discussion
Chair Prof. Ralf René Reinert
ESCMID-appointed Chair Prof. Marc J.M. Bonten
Dr. Peter Paradiso
Prof. Antoni Torres


mRNA Vaccines: The Accelerated Development of a COVID-19 Vaccine Including Clinical Development and Early Data on Effectiveness
Dr. Özlem Türeci (Germany)


Question and Answer Session
Prof. Ralf René Reinert
Dr. Özlem Türeci


Closing Remarks
Chair Prof. Ralf René Reinert
ESCMID-appointed Chair Prof. Marc J.M. Bonten

We hope that you can join us for what promises to be an engaging and educational event!

The approval status of the Pfizer-BioNTech COVID 19 Vaccine varies worldwide. In countries where the vaccine has not been approved by the relevant regulatory authority, it is an investigational drug, and its safety and efficacy have not been established. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the United States FDA but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

The EU SmPC in different languages for Prevenar13 can be accessed here:
Prevenar 13 | European Medicines Agency (europa.eu)
The EU SmPC in different languages for Comirnaty can be accessed here:
Comirnaty | European Medicines Agency (europa.eu)


Date of preparation: June 2021

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.